首页> 外文期刊>Anti-cancer drugs >Cytotoxicity of a recombinant fusion protein of adenovirus early region 4 open reading frame 4 (E4orf4) and human epidermal growth factor on p53-deficient tumor cells.
【24h】

Cytotoxicity of a recombinant fusion protein of adenovirus early region 4 open reading frame 4 (E4orf4) and human epidermal growth factor on p53-deficient tumor cells.

机译:腺病毒4区早期阅读框4(E4orf4)和人表皮生长因子重组融合蛋白对p53缺陷型肿瘤细胞的细胞毒性。

获取原文
获取原文并翻译 | 示例
           

摘要

Adenovirus early region 4 open reading frame 4 (E4orf4) protein is a novel cell death factor that selectively induces p53-independent apoptosis in cancer cells, but not in normal human cells. This study presents an approach for inhibiting p53-deficient tumor cell growth by using protein-based E4orf4 that had been genetically fused to epidermal growth factor (EGF) to ensure selective targeting of EGF receptor-overexpressing tumor cells. EGF-E4orf4 enables binding onto the cell surface and is then internalized into Saos-2 cells. The success of the process had been demonstrated by immunofluorescence assay and confocal laser microscopy. After prolonged exposure, E4orf4 remained mostly in the nuclei. EGF-E4orf4 treatment of Saos-2 cells showed dose-dependent cytotoxicity. Nearly 50% of the Saos-2 cells were killed at a concentration of 250 nmol/l. In contrast, EGF-E4orf4 showed no significant inhibitory effect iresn primary cells of human umbilical vein endothelial cells. To confirm the ability of EGF-E4orf4 to induce apoptosis, DNA fragmentation was detected using BrdUTP end-labeling. Flow cytometric analysis revealed a significant increase of apoptotic cells in Saos-2 cells treated with EGF-E4orf4, but not in the case of cells cultured in plain medium (t=0.028, P<0.05). In conclusion, these preliminary results indicate that EGF-E4orf4 could show promise as a new reagent that is more efficient and less toxic in anti-cancer therapy.
机译:腺病毒4区早期开放阅读框4(E4orf4)蛋白是一种新型细胞死亡因子,可选择性诱导癌细胞(而非正常人细胞)中不依赖p53的凋亡。这项研究提出了一种方法,该方法通过使用已经与表皮生长因子(EGF)遗传融合的基于蛋白质的E4orf4来抑制p53缺陷的肿瘤细胞生长,以确保选择性靶向过度表达EGF受体的肿瘤细胞。 EGF-E4orf4能够结合到细胞表面,然后被内在化成Saos-2细胞。通过免疫荧光测定和共聚焦激光显微镜证明了该方法的成功。长时间暴露后,E4orf4大部分保留在细胞核中。 EGF-E4orf4处理Saos-2细胞显示出剂量依赖性细胞毒性。以250 nmol / l的浓度杀死了近50%的Saos-2细胞。相反,EGF-E4orf4对人脐静脉内皮细胞的原代细胞没有明显的抑制作用。为了确认EGF-E4orf4诱导凋亡的能力,使用BrdUTP末端标记检测了DNA片段化。流式细胞仪分析显示在用EGF-E4orf4处理的Saos-2细胞中凋亡细胞显着增加,但在普通培养基中培养的细胞则无此现象(t = 0.028,P <0.05)。总而言之,这些初步结果表明,EGF-E4orf4有望作为一种新药,在抗癌治疗中更有效且毒性更低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号